A Comprehensive Immunotherapy Checklist for Patients Starting Treatment

Recent Trends

Immunotherapy has expanded rapidly from niche clinical trials to a standard option across multiple cancer types. Over the past several years, approvals for checkpoint inhibitors, CAR‑T cell therapies, and bispecific antibodies have increased, and many patients now face the decision of starting immunotherapy earlier in their treatment pathway. This shift has created demand for practical guidance that helps patients prepare for the unique side effect profiles, monitoring schedules, and coordination required.

Background

Immunotherapy works by harnessing the patient’s own immune system to recognize and attack cancer cells. Unlike chemotherapy, it does not directly kill tumor cells but rather removes the “brakes” on immune cells. This mechanism means that responses can be delayed or prolonged, and adverse events often resemble autoimmune conditions (e.g., colitis, dermatitis, pneumonitis, endocrinopathies). A structured checklist before starting treatment can help patients:

• Understand the specific drug class and how it is administered (intravenous, subcutaneous, oral).
• Confirm baseline lab work, including thyroid function, liver enzymes, and blood counts.
• Identify whom to contact for side effects outside office hours.
• Establish medication and supplement reconciliation with the oncology team.
• Arrange for a caregiver or support system during the first cycles.

User Concerns

Patients often worry about unpredictable side effects, delayed response, or the need for concurrent medications such as steroids or immunosuppressants. Common concerns that a comprehensive checklist addresses include:

• Side‑effect recognition: Knowing which symptoms (e.g., new rash, diarrhea, shortness of breath, fatigue) warrant immediate contact versus routine reporting.
• Infection risk: Immunotherapy does not typically cause the same immunosuppression as chemotherapy, but concurrent steroid use or underlying autoimmune disease may increase infection risk.
• Diet and lifestyle: No specific “immunotherapy diet” is proven, but a balanced intake, adequate hydration, and avoiding known immune triggers (e.g., raw foods if neutropenic) are commonly discussed.
• Vaccination timing: Live vaccines are generally contraindicated during immunotherapy; inactivated vaccines such as influenza and COVID‑19 are often allowed but should be timed away from treatment doses.
• Financial and logistical planning: Infusion centers, insurance pre‑authorizations, and travel to appointments can be burdensome; a checklist helps document these steps.

Likely Impact

Adoption of a systematic immunotherapy checklist can reduce anxiety and improve early detection of immune‑related adverse events. In clinical practice, standardized patient education materials have been associated with fewer emergency visits and better adherence to scheduled doses. For healthcare systems, checklists streamline multidisciplinary communication among oncologists, nurses, pharmacists, and emergency departments. The main risk is that patients may over‑interpret minor symptoms as serious, so the checklist must include realistic thresholds for when to call the clinic.

What to Watch Next

Future updates to the checklist will likely incorporate:

• Biomarker‑specific guidance: As PD‑L1 expression, tumor mutational burden, and microsatellite instability become routine, the checklist may include pre‑treatment test confirmation.
• Combination regimens: Many patients now receive immunotherapy plus chemotherapy or targeted therapy, which alters side‑effect profiles and monitoring intervals.
• Telehealth integration: Virtual check‑ins before and after infusions are becoming common; checklists will need to accommodate remote symptom reporting and video triage.
• Long‑term survivorship: Patients who discontinue immunotherapy after a complete response still require surveillance for late‑onset autoimmune effects; a separate follow‑up checklist will be needed.